Revolution Medicines, Inc. provided earnings guidance for full year 2024. For the year, the company expects GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million. Based on the company?s current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.